While MMR‐deficient CRC may have a more favourable stage‐matched prognosis compared to MMR‐proficient tumours [32], they are also relatively resistant to 5‐fluorouracil‐based chemotherapy [33]. The gene discussed is MRC1; the disease is colorectal carcinoma.